Director/PDMR Shareholding
2nd Oct 2025 07:00
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Director/PDMR Shareholding
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, announces that the Company has been informed that David Blain, a Director of the Company, made the following purchase of ordinary shares in the capital of the Company. Further details are set out in the Notification of Dealing Form below.
Director | Purchase price | Ordinary shares purchased | Resultant interest in ordinary shares | Resultant percentage of issued ordinary shares |
David Blain | 11.75 pence | 84,053 | 84,053 | 0.08% |
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc | www.optibiotix.com | |
Neil Davidson, Chairman |
| |
Stephen O'Hara, Chief Executive | ||
|
| |
Cairn Financial Advisers LLP (NOMAD and Broker) | Tel: 020 7213 0880 | |
Liam Murray / Ludovico Lazzaretti / James Western | ||
| ||
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | David Blain | |||||
2 | Reason for notification | ||||||
a. | Position/Status | Finance Director | |||||
b. | Initial notification/ Amendment | Initial Notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | OptiBiotix Health Plc | |||||
b. | LEI | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 2p each
ISIN: GB00BP0RTP38 | |||||
b. | Nature of the transaction | Purchase of ordinary shares
| |||||
c. | Price(s) and volume(s) | ||||||
Price(s) per share | Volume(s) | ||||||
11.75 pence | 84,053 | ||||||
d. | Aggregated information - Volume - Price |
84,053 shares 11.75 pence per share | |||||
e. | Date of the transaction | 1 October 2025 | |||||
f. | Place of the transaction | London Alternative Market (AIMX) | |||||